Afinitor for pancreatic neuroendocrine tumours - Details


( Last Updated : September 18, 2012)
Generic Name:
Everolimus
Project Status:
Complete
Therapeutic Area:
Pancreatic Neuroendocrine Tumour
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Project Line:
Reimbursement Review
Project Number:
PC0007-000
NOC Date:

Details


Strength:
2.5 mg, 5 mg and 10 mg
Tumour Type:
Gastrointestinal
Indications:
Pancreatic neuroendocrine tumours
Funding Request:
Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease.
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.